Denosumab biosimilar(Shanghai Hansoh)

地舒单抗生物类似药（上海翰森）

Report date: 2022/10/25 20:00:47

Base Information

Drug NameDenosumab biosimilar(Shanghai Hansoh)
Drug Alias NameDenosumab biosimilar(Reliance Life Sciences)Recombinant aiti-RANKL human monoclonal antibody (Shanghai Hansoh)HS-20090HS-20090-2
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Biosimilar
Mechanisms of ActionTumor necrosis factor ligand superfamily member 11 inhibitors
TargetsTumor necrosis factor ligand superfamily member 11
Therapy Area/IndicationsBone metastasesSolid tumoursHypercalcemia +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesShanghai Hansoh Biomedical Co LtdJiangsu Hansoh Pharmaceutical Group Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesJiangsu Hansoh Pharmaceutical Group Co LtdShanghai Hansoh Biomedical Co Ltd
Inactive CompaniesN/A
Active IndicationsBone metastasesSolid tumoursHypercalcemia +[5] 
Inactive IndicationsNutritional and Metabolic DiseasesOsteoporosis, PostmenopausalBone Diseases +[4] 

Other Information

ATC CodeN/A
Related LinksN/A